Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22

Despite high remission rates following CAR-T cell therapy in B-ALL, relapse due to loss of the targeted antigen is increasingly recognized as a mechanism of immune escape. We hypothesized that simultaneous targeting of CD19 and CD22 may reduce the likelihood of antigen loss, thus improving sustained...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Haiying, Ramakrishna, Sneha, Nguyen, Sang, Fountaine, Thomas J., Ponduri, Anusha, Stetler-Stevenson, Maryalice, Yuan, Constance M., Haso, Waleed, Shern, Jack F., Shah, Nirali N., Fry, Terry J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300726/
https://www.ncbi.nlm.nih.gov/pubmed/30581986
http://dx.doi.org/10.1016/j.omto.2018.10.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300726/
https://www.ncbi.nlm.nih.gov/pubmed/30581986
http://dx.doi.org/10.1016/j.omto.2018.10.006

Ejemplares similares